Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

32.51
+0.11000.34%
Volume:11.67M
Turnover:379.83M
Market Cap:37.30B
PE:52.68
High:32.87
Open:32.38
Low:32.20
Close:32.40
52wk High:32.91
52wk Low:12.47
Shares:1.15B
Float Shares:1.14B
Volume Ratio:1.04
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6171
EPS(LYR):-1.4492
ROE:9.71%
ROA:5.49%
PB:5.14
PE(LYR):-22.43

Loading ...

Truist Securities Adjusts Price Target on Teva Pharmaceutical Industries to $36 From $32, Maintains Buy Rating

MT Newswires Live
·
Jan 07

Teva Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
Jan 07

Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound

Simply Wall St.
·
Jan 05

Teva Pharmaceutical Credit Rating Raised by S&P, Moody's Upgrades Outlook

MT Newswires Live
·
Dec 24, 2025

Teva Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Dec 22, 2025

Teva Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Dec 20, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

GlobeNewswire
·
Dec 19, 2025

BRIEF-Alvotech and Teva Secure U.S. Settlement Date For AVT06

Reuters
·
Dec 19, 2025

Alvotech Sa - License Entry Date for Avt06 in U.S. Set for Q4 2026

THOMSON REUTERS
·
Dec 19, 2025

Sagimet Biosciences Shares Rise on Licensing Agreement With Teva

Dow Jones
·
Dec 18, 2025

Teva Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Dec 17, 2025

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Dec 10, 2025

Teva Pharmaceuticals Submits FDA Application for Monthly Schizophrenia Treatment

MT Newswires Live
·
Dec 09, 2025

Teva Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Dec 09, 2025

Teva Pharmaceuticals Initiated at Sector Outperform by Scotiabank

Dow Jones
·
Dec 05, 2025

Scotiabank Initiates Teva Pharmaceutical Industries With Sector Outperform Rating, $35 Price Target

MT Newswires Live
·
Dec 05, 2025

The Bull Case For Teva (TEVA) Could Change Following Launch Of Teva Rise Innovation Platform

Simply Wall St.
·
Dec 03, 2025

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Teva Pharmaceutical (TEVA)

TIPRANKS
·
Nov 27, 2025

Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation After European Approval for Key Biosimilars

Simply Wall St.
·
Nov 27, 2025

Jefferies Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Nov 26, 2025